Medherant said today that it successfully finished two Phase I studies with its ibuprofen transdermal drug-delivery patch. According to the UK-based company, the Tepi patch was well tolerated by the participants of a skin irritation study. Get the full story at our sister site, Drug Delivery Business News.
medherant
Medherant wins grant to support manufacturing program for transdermal drug-delivery patches
Medherant said today that it was awarded a Medicines Manufacturing Grant from Innovate UK to support the manufacturing of transdermal drug-delivery patches. The company plans to expand its pilot-scale GMP manufacturing program, which is designed to make patches formulated with its Tepi patch tech for clinical trials. Get the full story at our sister site, Drug […]
Anika CEO retires after two decades; president assumes corner office | Personnel Moves – March 13, 2018
Anika Therapeutics (NSDQ:ANIK) announced this month that CEO Charles Sherwood plans to retire after working for Anika for nearly twenty years. Joseph Darling, who has been Anika’s president since July 2017, will take his place in the corner office. Darling has previously served in executive leadership roles across an array of medtech companies like Abbott (NYSE:ABT), Baxter (NYSE:BAX) and Smith & Nephew (NYSE:SNN). […]
Medherant raises $5m to move transdermal ibuprofen patch to clinical trials
Transdermal drug-delivery company Medherant said yesterday it raised $5.1 million (GBP £3.8 million) in a funding round as it looks to move its drug-delivering ibuprofen Tepi Patch into clinical development early next year. The funding round was led by majority shareholder Mercia Technologies and joined by existing shareholders and new private investors, the Coventry, U.K.-based […]
